Kimberly Badiola
Primary Care · Henderson, NVNPI 1952917833
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novo Nordisk at 25.7% of the total. Reporting peaked in 2022 at $265 and has fallen 89.9% since, to $27 in 2023. That places this record below the midpoint for primary care clinicians in NV, where the typical reported total is $343.
Across 22 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$100
- Biohaven Pharmaceutical Holding Company Ltd.$54
- Boehringer Ingelheim$52
- Lilly USA, LLC$33
- AbbVie$27
- Esperion Therapeutics, Inc.$18
- plus $105 from 7 others
What the payments were for
- Food & beverage$388100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$388 in reported general payments places this provider in the 50th percentile of 81 primary care providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 19 | $24,413 |
| EliquisApixaban | 25 | $21,181 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,940 |
| Atorvastatin Calcium | 188 | $1,503 |
| Omeprazole | 73 | $1,374 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $983 |
| Amlodipine Besylate | 109 | $714 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 20 | $713 |
| Levothyroxine Sodium | 81 | $667 |
| Lisinopril | 97 | $594 |
| Alendronate Sodium | 52 | $569 |
| Losartan Potassium | 65 | $557 |
| Glipizide | 20 | $554 |
| Rosuvastatin Calcium | 61 | $528 |
| Famotidine | 17 | $393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $52 | $24,41319 claims |
| PfizerEliquis | $17 | $21,18125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 81 primary care providers in Nevada.
Other primary care in Henderson
- William EmmerlingHenderson$3K
- Alexandria LightningHenderson$2K
- Camatchy RadjassegaraneHenderson$279
- Brianemmanuel del RosarioHenderson$238
- Maria RainesHenderson$224
- Jennifer CribbLas Vegas$7K
- Lara MoralesSparks$6K
- Ruel MarianoLas Vegas$4K
- George Gabriel ToldnessLas Vegas$4K
- Jona SteadLas Vegas$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.